Toxic Maculopathy
Conditions
Keywords
Autoimmune Disease, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Hydroxychloroquine(HCQ), Chloroquine(CQ), Toxic Maculopathy
Brief summary
The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.
Interventions
PROCEDUREComposite Examination
First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE * Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy
Exclusion criteria
* Aged less than 19 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of toxic maculopathy associated with HCQ or CQ | 1 years |
Secondary
| Measure | Time frame |
|---|---|
| Risk factor of HCQ/CQ retinopathy | 5 years |
| Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy) | 5 years |
| Progression of retinopathy after drug cessation | 1 years |
Countries
South Korea
Contacts
Primary ContactJooYong Lee
Backup ContactByung-gil Moon
Outcome results
None listed